Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

News

Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

gbafNews28

CHICAGO, May 31, 2020 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a patient’s homologous recombination deficiency (HRD) status, and Tempus|TO, a test which predicts the tissue of origin (TO) for tumors, will both launch this summer in the U.S.

“Our existing suite of genomic sequencing tests provide physicians with critical data that informs patient care across solid tumor and liquid biopsy profiling,” said Eric Lefkofsky, Founder and CEO. “With our additional HRD and TO capabilities, we are able to further expand the data we can provide oncologists at the point of care, advancing our collective ability to be more precise for the benefit of patients.”

Tempus|HRD is a DNA-based test, available as a supplementary option to xT, the company’s signature broad-panel genomic sequencing test that measures 648 genes, along with the full transcriptome. It analyzes 18 of the commonly mutated genes in the HR pathway and calculates a genome-wide loss-of-heterozygosity (LOH) score to give clinicians a comprehensive view into a patient’s ability to repair cellular damage. A patient’s HRD status has been shown to identify whether or not they are a good candidate for PARP inhibitors and platinum-based chemotherapy. Tempus|HRD does not require any additional tissue from the patient and features unique positivity thresholds for Ovarian Cancer, Breast Cancer, and Pancreatic Cancer, along with a general threshold for all other solid tumors. The test incorporates data from both the tumor and normal tissue to ensure that the HRD test accurately reflects a patient’s specific tumor makeup. Tempus|HRD is launching this week in limited markets for all cancer types, with a broad launch slated for July.

Tempus|TO is an RNA-based sequencing test that provides guidance for physicians in cases in which imaging and immunohistochemistry stains yield uncertainty about the diagnosis of a patient’s tumor. The Tempus|TO test compares a patient’s tumor molecular data to a large internal database of annotated tumor data to identify a likely diagnosis that may impact standard of care therapy decisions, clinical trial enrollment, and reimbursement for therapies. Given that Tempus performs transcriptomic profiling on the vast majority of its patients, it is uniquely positioned by virtue of the size of its internal RNA database to identify a tumor’s tissue of origin. Tempus|TO is available in limited markets, with a broad launch planned for this summer.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Erin Carron communications@tempus.com

Primary Logo

Advertisement
Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now

Recommended

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.